"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population

NCT02248311 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2018-01-23

No results posted yet for this study

Summary

Current methods based on traditional Cardiovascular risk factors are not clinically useful for identifying Type 2 Diabetes patients at risk of developing acute Cardiovascular ischemic events (ie.myocardial infarction or stroke). In addition, Cardiovascular ischemic events in Type 2 Diabetes population have worse prognosis than in general population. In fact, there is sufficient experimental evidence indicating that diabetes exaggerates the deleterious effects of ischemic events and worsens their outcome.

A prolonged sub-clinical phase exists before a Cardiovascular event occurs in Type 2 Diabetes patients. Therefore, new strategies aimed at identifying those patients with this subclinical Cardiovascular Diabetes and, consequently, more prone to develop Cardiovascular events is a challenge to be met.

Conditions

  • Type2 Diabetes Mellitus
  • Microangiopathy
  • Non Alcoholic Fatty Liver Disease
  • Coronary Artery Disease
  • Cerebrovascular Disease
  • Acute Coronary Syndrome/ Myocardial Infarction
  • Ictus

Sponsors & Collaborators

  • Hospital Universitari Vall d'Hebron Research Institute

    lead OTHER

Principal Investigators

  • David García-Dorado Garcia, PhD MD · Hospital Universitario Valle de Hebron, Barcelona, Spain

  • Joan Montaner Vilallonga, PhD MD · Hospital Universitario Valle de Hebron, Barcelona, Spain

  • Rafael Simó Canonge, PhD MD · Hospital Universitario Valle de Hebron, Barcelona, Spain

  • Joan Sayós Ortega, PhD MD · Hospital Universitario Valle de Hebron, Barcelona, Spain

  • Daniel Serón Micas, PhD MD · Hospital Universitario Valle de Hebron, Barcelona, Spain

  • Joan Genescà Ferrer, PhD MD · Hospital Universitario Valle de Hebron, Barcelona, Spain

  • Santiago Aguadé Bruix, PhD MD · Hospital Universitario Valle de Hebron, Barcelona, Spain

  • Joan Xavier Comella Carnicé, PhD MD · Hospital Universitario Valle de Hebron, Barcelona, Spain

Eligibility

Min Age
50 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2018-02-28
Completion
2018-10-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02248311 on ClinicalTrials.gov